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Genetic Variants of Platelet Glycoprotein Receptors and
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Background and Purpose—A number of studies have examined the relationship between genetic platelet glycoprotein
variants and early-onset atherothrombotic disease, particularly acute myocardial infarction. Data on the association of
these genetic susceptibility markers with ischemic stroke are more limited, and their role in hemorrhagic stroke has not
been previously examined.
Methods—We performed genotype analysis for 5 cornmon diallelic platelet glycoprotein polymorphisms in a population-
based study of 78 white women aged <45 years with arterial stroke (36 ischemic cases and 42 hemorrhagic cases) and
346 demographically similar control subjects.
Results—The 807T variant of glycoprotein la was associated with a 2-fold increased risk of ischemic stroke (age-adjusted
odds ratio [OR]=2.24; 95% CI=0.99 to 5.06). The Met145 allele of glycoprotein Iba was associated with a trend toward
an increased risk of ischemic stroke that was more pronounced in the homozygous state (OR= 10.36), but the CI is
extremely wide because of the small numbers of subjects (95% CI= 1.43 to 79.34). Homozygosity for the Ser843 allele
of the glycoprotein Ilb was associated with an ^5-fold increased risk of ischemic stroke among subgroups of women
who carried a diagnosis of hypertension or diabetes (OR=4.51; 95% CI=1.01 to 20.13) or had elevated plasma
homocysteine levels (OR=5.94; 95% CI=1.53 to 23.05). The genotype distributions for all 5 platelet glycoprotein
polymorphisms were similar among hemorrhagic stroke cases and controls.
Conclusions—Several inherited platelet glycoprotein variants may be associated with an increased risk of ischemic stroke
in young women. These associations seemed to be confined to women with other cardiovascular risk factors. Additional
studies involving larger numbers of subjects are needed to confirm these preliminary findings. (Stroke.
2000;31:1628-1633.)
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Platelet thrombosis is mediated by several platelet mem-brane receptor complexes, including glycoprotein Ib/IX,
glycoprotein la/IIa, and glycoprotein Ilb/IIIa (Table 1). Sev-
eral genetic platelet glycoprotein variants have been associ-
ated with an increased risk of early-onset atherothrombotic
disease, particularly acute myocardial infarction.1 The poten-
tial contributions of these genetic platelet glycoprotein vari-
ants to the occurrence of ischemic stroke have been examined
in a smaller number of studies. The Pro33 variant of platelet
glycoprotein lila and the Met'45/VNTR-B allele of glycopro-
tein Iba have been associated with ischemic stroke in some
studies, but not in others.2~8 Two other common platelet
glycoprotein dimorphisms, glycoprotein Ilb Ile/Ser843 and
glycoprotein la Glu/Lys505, were not associated with ischemic
stroke in a single study,7 but the Ile843 variant of glycoprotein
Ilb was recently associated with increased mortality follow-
ing ischemic stroke in an elderly patient population.9 A
nucleotide 807T variant of glycoprotein la that correlates
with increased platelet surface levels of glycoprotein la/IIa
(the platelet collagen receptor)10 was recently associated with
an increased risk of ischemic stroke with onset at a young
age.11
The inconsistent results of studies examining the risk of
stroke associated with genetic platelet glycoprotein variants
may be partly due to differences in demographic character-
istics between study populations. For example, genetic pro-
thrombotic factors may be more important in younger indi-
viduals or premenopausal women'2·13 who are less likely to
have advanced atherosclerotic disease. Furthermore, the ef-
fect of single genetic factors on the risk of stroke may be
weak when analyzed individually but may be more pro-
nounced in the presence of other common genetic or envi-
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vWF indicates von Willebrand factor; VNTR, variable number of tandem repeats.
ronmental cardiovascular risk factors (eg, hypertension,
smoking, obesity). We therefore assessed the association of 5
common platelet glycoprotein polymorphisms with stroke in
young women (aged <45 years) and examined potential
interactions between these genetic variants and other tradi-
tional cardiovascular risk factors.
Subjects and Methode
This analysis is based on data and genetic material collected in a
population-based case-control study of incident nonfatal stroke in
young women.14·13 The study population consisted of women aged
18 to 44 years residing in 3 contiguous counties in western
Washington State between July l, 1991, and February 28, 1995. All
subjects gave informed consent according to a protocol approved by
the University of Washington and participating local hospitals.
Stroke was defined äs evidence of new focal neurological deficit(s)
with no other apparent cause (ie, brain tumor, infection, subdural
hematoma, seizure, or other neurological condition) lasting >24
hours. On the basis of review of hospital records, brain imaging
studies, and lumbar puncture results, strokes were further classifled
by the study neurologist (W.T.L.) äs ischemic, hemorrhagic, venous,
or "other" (including arterial dissections). Random-digit telephone
dialing was used to identify female control subjects, who were
frequency matched to the age distribution of the cases.
One hundred forty-nine of 198 eligible patients with nonfatal
stroke and 525 of 684 eligible control subjects were willing to
participate ih an in-person interview. The interview involved ascer-
tainment of demographic characteristics and histories of traditional
cardiovascular risk factors, including hypertension, diabetes, ciga-
rette smoking, hypercholesterolemia, height, weight, contraceptive
practices, menstrual Status, and frequency of vigorous exercise. All
interview questions elicited Information about the time period before
each subject's reference date, which was the date of stroke for cases
and a date assigned at random from among the potential stroke
occurrence dates for controls. A woman was classified äs hyperten-
sive, diabetic, or hypercholesterolemic if she reported ever receiving
the diagnosis by a physician. Smokers were defined äs subjects who
reported smoking both currently (within a month of the reference
date) and regularly (a5 cigarettes per week for 2:6 consecutive
months). Obesity was defined äs a body mass index £:27.3 kg/m .
Physical inactivity was defined äs exercising vigorously <1 time per
week. Hyperhomocysteinemia was defined äs a serum homocysteine
level >12.6 μηιοΙ/L.
At the time of interview, venous blood samples were collected into
EDTA-treated evacuated tubes from 106 participating stroke cases (54
hemorrhagic, 41 ischemic, 2 venous, and 9 "other") and from 391
participating control subjects. Plasma and genomic DNA samples were
prepared äs described previously.14·15 Genotyping for 5 platelet glyco-
protein polymorphisms (glycoprotein lila Leu/Pro33, glycoprotein llb
Ile/Ser843, glycoprotein Iba Thr/Met145, glycoprotein la Glu/Lys505, and
glycoprotein la C807T) was performed by polymerase chain reaction
amplification of genomic DNA followed by restriction enzyme digestion
(polymerase chain reaction-restriction fragment length polymorphism),
according to previously published methods.16-18
In a previous analysis of the overall study sample, we determined that
there was a significantly greater proportion of black women among the
hemorrhagic stroke cases (11.8%) and ischemic stroke cases (11.7%)
man among the control subjects (2.5%).14 Since the distnbution of
platelet glycoprotein alleles differs according to race, white and black
subjects must be analyzed separately. However, because of the inade-
quate number of black women in the control group, we restricted the
companson of platelet glycoprotein genotypes to the subset of study
subjects with DNA samples who were white (36 ischemic stroke cases,
42 hemorrhagic stroke cases, and 346 controls).
Platelet glycoprotein allele frequencies were calculated by gene
counting. The association of platelet glycoprotein genotypes with stroke
was examined by unconditional logistic regression adjusted for age and
was expressed äs odds ratios (ORs) and 95% CIs. Unless otherwise
noted, ORs for the 5 biallelic platelet glycoprotein polymorphisms were
calculated comparing individuals who were either heterozygous or
homozygous for the less common allele with individuals who were
homozygous for the more common allele. We also assessed the extent to
which associations with platelet glycoprotein polymorphisms were mod-
ified by other cardiovascular risk factors, including smoking, obesity,
hypertension, diabetes, and hyperhomocysteinemia, through analyses
stratified on these cardiovascular risk factors.
Results
A comparison of the characteristics of stroke cases and
control subjects among the subset of white women with DNA
samples is presented in Table 2. The frequencies of various
cardiovascular risk factors among ischemic stroke cases,
hemorrhagic stroke cases, and control subjects were similar to
those previously reported in an analysis based on a larger
sample size from this study population.14 Current cigarette
smoking, hypertension, and physical inactivity were more
common in both ischemic stroke cases and hemorrhagic
stroke cases than control subjects. Higher plasma levels of
total homocysteine were also noted in both the ischemic and
hemorrhagic stroke patients compared with control subjects.
In contrast, higher frequencies of obesity and diabetes were
confined to the ischemic stroke cases.
The genotype distributions of the 5 platelet glycoprotein
polymorphisms among the ischemic stroke cases and control
subjects are compared in Table 3. A trend toward an associ-
ation with risk of ischemic stroke was observed for the
glycoprotein la C807T, glycoprotein Iba Thr/Met145, and
glycoprotein llb Ile/Ser843 polymorphisms, but none of these
reached the level of statistical significance in the overall
study sample. The age-adjusted OR for women carrying a l
copy of the 807T allele was 2.24, and the lower confidence
limit was just <1.0 (95% CI=0.99 to 5.06). When analyzed
by subgroups defined according to the presence or absence of
other cardiovascular risk factors, the risk of ischemic stroke
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associated with the 807T allele was highest in the subgroup of
women (16 cases and 91 controls) who were obese
(OR=3.24; 95% CI=0.86 to 12.18) and in the subgroup of
women (13 cases and 86 controls) who had elevated plasma
homocysteine levels (OR=4.03; 95% CI=0.83 to 19.67).
The presence of > l copy of the Met145 allele of glycopro-
tein Iba was associated with a more modestly increased risk
of ischemic stroke (OR=1.48; 95% CI=0.64 to 3.41). The
risk associated with the Met145 allele of glycoprotein Iba was
highest in the subgroup of women (15 cases and 40 controls)
who carried a diagnosis of either hypertension or diabetes
(OR=3.86; 95% CI=0.98 to 15.17). In the overall study
population, the increased risk associated with the Met145
variant was primarily due to an overrepresentation of the
Met/Met145 genotype among the ischemic stroke cases (5.6%)
compared with the controls (0.6%). This results in a large
point estimate for the risk of ischemic stroke associated with
Met145 homozygosity (age-adjusted OR= 10.63), but the CI is
extremely wide (95% CI=1.43 to 79.34) because of the
relatively low frequency of this genotype.
Homozygosity for the Ser843 allele of glycoprotein Ilb was
also more prevalent in ischemic stroke cases (22.2%) than
controls (14.4%) (OR=1.69; 95% CI=0.73 to 3.92). The risk
of ischemic stroke associated with carrying 2 copies of the
Ser843 allele was particularly high in the subgroup of women
with hypertension or diabetes (OR=4.51; 95% CI=1.01 to
20.13) and in the subgroup of women with elevated plasma
homocysteine levels (OR=5.94; 95% CI=1.53 to 23.05). By






































































































*ORs are adjusted for age and calculated comparing carriers of 1 or 2 copies of the less common allele (eg, carners of glycoprotein
Ilb Ser843) to individuals who are homozygous for the more common allele (eg, carriers of glycoprotein Ilb lle843/!̂ 843 genotype).
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*ORs are adjusted for age and calculated comparing carners of 1 or 2 copies of the less common allele (eg, carners of glycoprotein
llb Ser843) to mdividuals who are homozygous for the more common allele (eg, carners of glycoprotein llb Ile843/lle843 genotype).
contrast, the risk associated with homozygosity for the
glycoprotein llb Ser843 allele was not increased in women
without hypertension or diabetes (OR=0.94; 95% CI=0.27
to 3.33) or in women with normal plasma homocysteine
levels (OR=0.83; 95% CI=0.23 to 2.94).
The genotype distributions of the 5 platelet glycoprotein
polymorphisms in hemorrhagic stroke cases and control
subjects are compared in Table 4. The genotype distributions
were similar between hemorrhagic stroke cases and controls,
either overall or in the presence or absence of other cardio-
vascular risk factors (data not shown).
Discussion
Our results suggest possible associations between 3 platelet
glycoprotein polymorphisms, glycoprotein la C807T, glyco-
protein llb Ile/Ser843, and glycoprotein Iba Thr/Met145, and
risk of ischemic stroke in young women. Although the
observed associations were modest, and the study was limited
by small numbers of stroke cases, 2 features of the study
suggest that these preliminary results may represent authentic
associations. First, there was evidence that the risk of ische-
mic stroke associated with these genetic platelet glycoprotein
variants was highest in subgroups of women with other
known cardiovascular risk factors. These results are consis-
tent with previous studies that indicate the importance of
genetic prothrombotic factors in combination with other
cardiovascular risk factors in the occurrence of atherothrom-
botic diseases such äs myocardial infarction in young
adults.19-21 Second, we did not observe an association be-
tween any of the platelet glycoprotein polymorphisms and
risk of hemorrhagic stroke, a disorder that does not involve
platelet-dependent thromboembolism.
Glycoprotein la/IIa is the major platelet collagen receptor
and is responsible for platelet adherence to exposed vascular
subendothelium. The 807T allele of glycoprotein la was
recently associated with a statistically significant 3-fold
increased risk of stroke in men and women aged <50 years
but was not associated with stroke in patients aged >50
years." Our results in young women indicate an «=2-fold
increased risk of ischemic stroke associated with the 807T
variant that was highest in women who were either obese or
had elevated plasma homocysteine levels. An increased risk
of myocardial infarction associated with the glycoprotein la
807T allele similarly has been reported in young obese men.22
The platelet glycoprotein Ib/IX complex is the major
platelet receptor for von Willebrand factor and is responsible
for initial platelet adhesion and activation following exposure
to vascular subendothelium under high shear rates. Gonzalez-
Conejero et al4 and Sonoda et al5 each reported a 2- to 3-fold
increased risk of ischemic stroke or transient ischemic attack
in men and women who possessed >1 copy of the Met145
allele. Our results indicate a trend toward an increased risk of
ischemic stroke associated with the presence of >1 copy of
the Met145 allele in young women, particularly in the sub-
group of women who were hypertensive or diabetic. More-
over, women who possessed 2 copies of the glycoprotein Iba
Met145 allele had an «=10-fold increased risk of ischemic
stroke, although this estimate of effect was statistically
unstable because of the small sample size and relatively low
frequency of the Met145 variant.
The bridging of adjacent platelets through the glycoprotein
Ilb/IIIa receptor is important for thrombus formation, and
glycoprotein Ilb/IIIa inhibitors are used increasingly in the
treatment of atherothrombotic disease. Carter et al2 reported
an association between the Pro33 variant of platelet glycopro-
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tein lila and risk of atherothrombotic stroke only in the
subgroup of patients aged <50 years. Wagner et al3 reported
a trend toward an association between the Pro33 variant of
platelet glycoprotein lila and cerebral infarction in women
aged <45 years when the analysis was restricted to whites. In
contrast, we found no association between the glycoprotein
lila Pro33 variant and risk of ischemic stroke in our population
of young white women. Our negative findings are consistent
with the results of 2 other case-control studies,6·7 äs well äs a
prospective study of male physicians.8
The platelet glycoprotein Ilb/IIIa receptor contains another
prevalent polymorphism, glycoprotein üb Ile/Ser843. Two
studies have not observed an association between the Ile/
Ser843 polymorphism of glycoprotein Ilb and risk of cerebro-
vascular disease in older patient populations.7·9 Our results
suggest a trend toward an association with increased risk of
ischemic stroke in young women who are homozygous for
the Ser843 variant. The risk associated with the glycoprotein
Ilb Ser/Ser843 genotype was most pronounced in women with
hypertension or diabetes (OR=4.51; 95% CI=1.01 to 20.13)
and in women with elevated plasma homocysteine levels
(OR=5.94; 95% CI=1.53 to 23.05). Although the CIs were
wide around these point estimates, they did not overlap 1.0. A
recent preliminary report indicated that platelets containing
the glycoprotein Ilb Ser843 allele demonstrate increased in
vitro platelet aggregation and clot retraction compared with
those lacking the Ser843 allele23 and thus provides a possible
explanation for the association between the Ser843 variant and
risk of atherothrombotic disease.
Our findings are in contrast with another recent study that
noted an association between the more common Ile843 variant
of glycoprotein Ilb and increased risk of poststroke mortality
in an older patient population.9 Since our study analyzed only
women who survived their acute event, it is possible that the
women who died acutely had an overrepresentation of the
Ile841 variant. Given the possible increased in vitro thrombo-
genicity of the Ser843 variant,23 one may speculate that the less
adhesive Ile843 allele is associated with a increased tendency
toward embolization of a preexisting platelet thrombus; this
might account for increased mortality following the acute
atherothrombotic event.9
Several limitations of our study should be noted. First,
the relatively small number of cases and the performance
of multiple subgroup analyses may increase the likelihood
of a spurious association (type I statistical error). In this
regard, some polymorphisms that have been associated
with stroke or myocardial infarction in smaller studies
have not been verified in larger, prospective studies.1·8
Second, the small number of cases decreases the likelihood
of detecting weak associations (type II error). Third, blood
samples for DNA analysis were collected at the time of
subject interview; thus, äs noted above, our study includes
only women who survived an acute stroke. Therefore, if a
particular platelet glycoprotein allele was associated with
increased morbidity or early mortality, the effect could be
underestimated because of exclusion of women who died
acutely or were severely disabled. Fourth, our results apply
to white, premenopausal women with acute stroke and may
not be generalized to other demographic and ethnic groups.
Thus, confirmation of the role of genetic platelet glyco-
protein variants äs risk factors for early-onset ischemic
stroke requires further study involving larger numbers of
subjects and other populations.
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